Zinc oxide nanoparticles regulate NF-kB expression and restrict inflammation response in Doxorubicin- induced kidney injury in rats

Zinc oxide nanoparticles regulate NF-kB expression and restrict inflammation response in Doxorubicin- induced kidney injury in rats | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Zinc oxide nanoparticles regulate NF-kB expression and restrict inflammation response in Doxorubicin- induced kidney injury in rats Ahlam Elgohary, Faten Metwalli, Nasser Mostafa, Manar reffat, and 1 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-2814493/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract This study evaluated the biochemical, molecular, and histopathological mechanisms involved in renal injury and the effect of zinc oxide nanoparticles (ZnONPs) in experimental nephrotoxicity rats. ZnONPs were prepared by the sol–gel method and characterised by scanning and transmission electron microscopy (SEM and TEM). To explore the possible nephrotoxicity and antioxidant effect of ZnONPs, rats were grouped as follows: control group, ZnONPs-treated group, Doxorubicin group, and ZnONPs-Doxorubicin-treated group. Upon treatment with ZnONPs, a significant alteration was observed in the activities of superoxide dismutase, glutathione peroxidase, malondialdehyde, catalase, and the levels of kidney function, albumin, albuminuria, immune nuclear factor kappa B (NF-B), and interleukin-6 (IL-6) compared to the Doxorubicin group and control group. ZnONPs' administration to the doxorubicin group showed eminent renal injury control and restoration of the biochemical profile. This increases their active role in controlling kidney function in order to improve nephrotoxicity and inflammatory responses. Histopathological and immunohistochemical observations provided context for these findings. In conclusion, ZnO-NPs treatment revealed a renoprotective effect against the doxorubicin drug, probably via its antioxidant, anti-inflammatory, and anti-apoptotic properties. This shows the therapeutic application of ZnONPs as a safe anti-inflammatory and shows their potential for the control of renal injury. Doxorubicin Kidney Injury Oxidative stress Zinc oxide Nanopartcle Gene expression. Figures Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Figure 6 Figure 7 Figure 8 Figure 9 1. Introduction Acute kidney injury (AKI) and chronic kidney disease (CKD) are linked to high morbidity and mortality. AKI is regarded as a rapid and reversible decline in renal function and is associated with accelerated CKD [1]. CKD is a significant medical problem globally, with a rapid increase in incidence due to the rise in hypertension and diabetes [2]. CKD also plays an important role in AKI. Patients with CKD are more likely to experience transient decreases in renal function consistent with AKI [3]. Furthermore, the syndrome is quite common among patients without a critical illness, and it is essential that health care professionals, particularly those without specialization in renal disorders, detect it easily. The classification of AKI includes pre-renal AKI, acute post-renal obstructive nephropathy, and intrinsic acute kidney diseases. Of these, only "intrinsic" AKI represents true kidney disease, while pre-renal and post-renal AKI are the consequence of extra-renal diseases leading to a decreased glomerular filtration rate (GFR). If these pre- and/or post-renal conditions continue, they will lead to renal cellular damage and, as a result, intrinsic renal disease [4,5]. The underlying mechanisms that result in acute renal dysfunction may involve decreased GFR, increased proteinuria, renal autoregulation failure, and drug-induced nephrotoxicity [6]. Doxorubicin (DOX), which is a member of the anthracycline family of cytotoxic antibiotics and one of the most potent and commonly used chemotherapeutic agents for the treatment of various types of cancer [7], The antitumor activity of doxorubicin is attributed to its ability to intercalate into the DNA helix and/or bind covalently to proteins involved in DNA replication and transcription, resulting in inhibition of DNA, RNA, and protein synthesis, leading finally to cell death [8]. Doxorubicin-based chemotherapy for the treatment of a wide spectrum of both hematological and solid tumors It is also associated with toxicities to different organs like the heart, kidney, liver, and testis [9]. The exact mechanism of DOX-induced nephrotoxicity is not yet known. Furthermore, it has been suggested by many investigators that DOX can induce the generation of reactive oxygen species (ROS), which cause damage to membranes and macromolecules through lipid peroxidation, oxidative stress, DNA fragmentation, and protein oxidation [10]. The increase in oxidative stress and depletion of endogenous antioxidants trigger the apoptotic pathway in the kidney [11, 12]. Available laboratory evidence shows that DOX induces nephropathy via its detrimental effects on renal tissue, including increased glomerular capillary permeability and glomerular atrophy, and accumulation of DOX in the glomerulus [13]. Therefore, administering drugs with anti-inflammatory and antioxidant effects could mitigate the side effects of DOX [14]. Nowadays, nanoparticles are primarily the most important aspect of nanotechnology because of their economic and commercial significance. Recent studies have shown the role of metals in life-threatening diseases [15, 16]. Nanoparticles are used in a variety of preclinical and clinical applications due to their unique properties, such as cellular uptake and delivery efficiency to biological systems. In the nanoscale dimension, nanoparticles (NPs) have different catalytic properties than larger particles of the same composition [17]. Nanoparticles, particles with a diameter less than 50 nm, have a lot of applications, including as drug carriers, which are important in the management of several disorders [18, 19].. Zinc oxide nanoparticles (ZnO-NPs) are one of the important nanoparticles that are commonly used in sunscreens, biosensors, pigments, food additives, and medicine [20]. Although several studies reported that ZnO-NPs have cytotoxic effects [21], other studies reported that they have antioxidant effects [22] and antibacterial effects [23]. Furthermore, ZnO-NPs inhibit the expression of several cytokines at the mRNA and protein levels, including IL6, IL-1, iNOS, COX-2, and TNF- [23]. Furthermore, it has anti-diabetic properties, as ZnO-NPs reduce oxidative stress in diabetic rats [24]. Due to the inherent toxicity of ZnO NPs, they possess strong inhibitory effects against cancerous cells and bacteria by inducing intracellular ROS generation and activating the apoptotic signaling pathway, which makes ZnO NPs a potential candidate as anticancer and antibacterial agents [25]. Although many studies have shown that ZnO-NPs have cytoprotective effects in various tissues [22-24], To the best of our knowledge, the effect of ZnO-NPs against renal IRI is the first one. Thus, the current study was designed to examine the effect of ZnO-NPs on renal I/R injury status and antioxidant profile. Then, we explored the effects on the expression of immune nuclear factor-kappa B (NF-B) and interleukin-6 (IL-6) and kidney function in addition to the histopathological picture of the kidney. This is all to provide evidence that will support therapeutic efforts to treat renal I/R injury with ZnONPs. 2. Material And Methods 2.1 Preparation of Dispersible ZnO Nanoparticles ( ZnONPs): ZnO nanoparticles were produced as follows: 40 mmoles of zinc sulphate (ZnSO4) and 40 mmoles of urea (CO(NH 2 ) 2 ) were dissolved in 1 litre of deionized water with vigorous stirring. A 3.0 M sodium hydroxide (NaOH) solution was added while stirring until the pH reached 12. The stirring continued for 30 minutes at room temperature. The solution was transported into a Teflon container open to the atmosphere and heated in microwave oven (2.45 GHz) at 800 watts of power for 10 minutes. After cooling to room temperature, the produced ZnO nanoparticles were centrifuged and washed with deionized water. Part of the ZnO nanoparticles were dried at 95 °C for XRD analysis, and the remaining part was dispersed in deionized water and kept in the refrigerator for use. According to Torabi et al. [26], ZnO NPs were then suspended in saline (0.9%) before use. and dispersed by ultrasonication to avoid particle aggregation. 2.2 Characterization of ZnONPs In the present study, the average particle size of nano-ZnO was less than 50 nm. X-ray diffraction (XRD) was used to determine the nature and size of ZnO crystalline phases. To confirm the size and determine the morphology and crystalline quality, nano-ZnO was investigated in detail via TEM (Tecnai G2 20 STWIN, Philips, Netherlands), and ZnO particle sizes were examined by scanning electron microscope (SEM, Hitachi S4800). Particles’ size and zeta potential were measured using dynamic light scattering (DLS, Zetasizer 5000, Malvern, Worcestershire, U.K.). 2.3 Experimental animals The present study included Fifty adult male albino rats aging 6 weeks, with an average body weight of 100 to120 g purchased from Holding Company for Biological Products and Vaccines, Cairo, Egypt. The rats were housed in groups in metal cages for bedding on a standard rat pellet diet and tap water adlabitum under controlled conditional of temperature (23.0±1.0 C°) and humidity at 55±10%with a 12 h light/dark cycle respectively for one week before and during the experiment. Animal treatments in this study were performed in compliance with the guidelines of the Guide for the Care and Use of Laboratory Animals and approved by Mansoura University animal care committee. 2.4 Animal grouping: Experimental design After an acclimatization period of one week, the rats were randomly distributed into five equal groups (n = 10). The experimental study period was four weeks, and the studied groups were as follows: In the control group ( CNT group), the rats were intraperitoneally (IP) injected with three equal injections at 4-day intervals over a period of two weeks, starting on the first day of the second week, with 500 l µl physiological saline. The rats in the nephrotoxic control group (DOX treated) were IP injected three times at four-day intervals for two weeks, beginning on the first day of the second week, with 500 l of DOX dissolved in physiological saline at a dose of 5 mg/kg BW, for a total cumulative dose of 15 mg/kg BW. ZnONP's normal treated group, The rats were administered with 200 l of ZnONPs solution, respectively, at a dose of 10 mg/kg BW, through IP (injected every day over a period of two weeks). The nephrotoxic group was treated with ZnONPs (DOX-ZNONPs group) , and the rats were given both DOX (as mentioned in the DOX group) at 5 mg/kg BW and 200 l of ZnONPs dissolved in physiological saline, respectively, at a dose of 10 mg/kg BW via IP, injected every day for two weeks (two weeks after DOX injection). 2.5 Collection of urine samples Urine samples were collected from all rats in each group, which were individually housed in metabolic cages to allow for 24-hour urine collection. Rats continued to have free access to water and a standard diet. Total urine volume was measured; 1 ml was collected from a 24-hour urine sample, stored at -80 °C, and used for the determination of urinary albumin excretion. 2.6 Biochemical assessment Blood samples were collected for measurement of creatinine using creatinine kits, Jaffé, colorimetric method—end point (Diamond Diagnostics Company, Hannover, Germany) according to manufacture instruction [27]; blood urea nitrogen (BUN) using urea kits, Berthelot enzymatic colorimetric method (Diamond Diagnostics Company, Hannover, Germany) according to manufacture instruction [28]; and albumin, ALT, and AST were measured spectrophotometrically in serum using biodiagnostic kits (BioMed Diagnostics Company, Badr, Egypt) according to manufacture instruction [29]; and Urinary albumin excretion (g/mL) was also measured using microalbuminuria kits (ABC Diagnostic, New Damietta, Egypt) and a rapid colorimetric method according to the manufacturer's instructions [30] Albuminuria was calculated as g/24 h by taking the urine volume (ml) in 24 hours into account. 2.7 Assessment of oxidative stress and inflammatory markers The right kidney of all rats was collected and homogenized in phosphate buffer (pH 7.4) to assess the level of oxidative stress markers (malondialdehyde "MDA," reduced glutathione "GSH," catalase "CA," and superoxide dismutase "SOD") and the inflammatory marker "IL-6" using specific kits according to the manufacturer's instructions. Kits for MDA (Cat. No. MD 25-29), GSH (Cat. No. GR 25-11), CA (Cat. No. CA 25-17), and SOD (Cat. No. SD 25-21) were purchased from the Bio-Diagnostic Company, Giza, Egypt; a rat IL-6 ELISA kit was purchased from the Bioassay Technology Laboratory Company (Cat. No. E0135Ra Shanghai, China). 2.8 Immunohistochemistry (IHC ( NF-B expression was evaluated on paraffin-embedded tissues by a standard immunostaining assay. Briefly, xylene and a graded alcohol series were used for deparaffinization and rehydration, respectively. Then the slides were incubated for 30 minutes in a blocking reagent containing 1.5 percent hydrogen peroxide in methanol. Antigens were retrieved and placed on slides using a microwave protocol. They were then incubated in serum for 30 min and immunostained with NF-B (cat. no. sc-48,366; Santa Cruz Biotechnology, Inc.) primary antibodies for 1 h at room temperature. Afterward, the slides were washed with PBS three times and then incubated with secondary antibodies for 30 min. The sections were stained using 3,30-diaminobenzidine (Dako liquid DAB color solution), and the slides were then counterstained with hematoxylin. An Olympus BX51 microscope (Olympus, Tokyo, Japan) was used to visualize the results. Five different microscopic fields were randomly selected from each slide, and positive staining within each slide was measured using Image-Pro Plus 6.1. Finally, quantitative analysis was performed in a blinded manner [31]. 2.9 Histopathological assessment All rats' left kidneys were perfused with neutral buffered formalin (10%) and processed in 5 m paraffin sections for histopathological examination. All kidney tissues were stained with hematoxylin and eosin (H&E), periodic acid Schiff (PAS), and Masson Trichrome. Changes in kidney structure were analyzed to assess the severity of the morphologic changes (glomerulosclerosis, interstitial inflammation, interstitial fibrosis tubular atrophy, "IFTA," and vascular lesions), and then each type of lesion was graded semi-quantitatively as described previously [32]. 2.10 Statistical analysis Data analysis was expressed as mean ± SEM. Difference between groups was detected using one way ANOVA followed with post Hoc Tukey test using SPSS software version 21 . Values at P < 0.05 were considered statically significant. 3. Results 3.1 XRD analysis of ZnO-NPs The phase of the as-synthesized ZnO products was determined using XRD, as shown in Fig. 1. XRD analysis reveals that the sample is a pure ZnO phase of the hexagonal ZnO phase (wurtzite-type structure, space group: P63mc (186). All the diffraction peaks were indexed to the (100), (002), (101), (102), (110), (103), (200), and (211) planes of the pure hexagonal wurtzite structure. No impurities were detected in these products. 3.2 SEM microstructure analysis The morphology of the samples was investigated using SEM. Figure 2 (a) shows the SEM micrographs. The SEM images show that the samples were agglomerated to some extent, and have an irregular spherical shape with a particle size The composition of the samples is determined using the EDX spectra obtained in conjunction with the SEM micrographs. Figure 2 (b) depicts the resulting EDX spectrum, where Zn and O peaks are clearly seen without any other peaks bearing any resemblance to other elements. 3.3 TEM analysis of ZnONPs The TEM observations illustrated that ZnONPs exhibited almost spherical Geometry with diameter about 30-50nm. (Fig. 3) 3.4 Detection of particle size analysis : The size distribution was determined by dynamic light scattering (DLS). They had a good dispersion, which is in good agreement with the DLS result shown in Fig 4. 3.5 zeta potential measurements: The zeta potentials of the synthesized NPs were detected from their electrophoretic mobilities using Microtrac and Nanotrac Wave II Q, and the zeta potential of the particles was -16.1 mV, which is of good quality, and Z-Average (d.nm.): 1239, as shown in Fig 5. 3. 6 Effects of ZnO-NPs on kidney and liver functions of experimental groups The treatment effect of ZnO-NPs on kidney dysfunction induced by doxorubicin is presented in Table1 and indicated by analyzing serum creatinine, BUN , albumin, AST and ALT. In doxorubicin treated group, serum creatinine, BUN were a highly significant increase when compared with the normal control group. While treated group with ZnO-NPs (10 mg/kg b.w./day) showed a highly significant reduction in serum creatinine, BUN levels when compared with the doxorubicin treated group (Table 1).While there was no significant change in serum creatinine, BUN levels in group treated withZnONPs ( 10 mg/kg b.w./day) when compared with the normal control group. There was a highly significant decrease in serum albumin level in doxorubicin treated group when compared with the normal control group(Table 1).While there was no significant change in serum albumin level in group treated with ZnONPs (10 mg/kg b.w./day) when compared with the normal control group. While there was ahighly significant increase in serum albumin level in treatment group with ZnO-NPs (10 mg/kg b.w./day when compared with the doxorubicin treated group (Table 1). Moreover, the effect of DOX resulted in a highly significant increase in serum AST and ALT levels compared to the normal control group. While there was no significant change in serum AST and ALT levels in the group treated with ZnONPs (10 mg/kg b.w./day) when compared to the normal control group, While there was a highly significant decrease in serum AST and ALT levels in the treatment group with ZnO-NPs (10 mg/kg b.w./day) when compared with the doxorubicin-treated group, Table1: The effects of DOX and/or ZnONPs on and Liver functions of experimental groups Note: Values are expressed as mean±SEM ; statistics were done using one-way ANOVA followed by Post Hoc Tukey test ) P value≤0.05 ( . a Highly significant in comparison with normal control group b Highly significant in comparison with doxorubicin treated group ; NS, not significant 3.7 Effects of ZnO-NPs on Albuminuria of experimental groups Figure 6 shows the serial changes of albuminuria (g/24 h) in the experimental groups. Albuminuria was significantly higher in the doxorubicin-treated group than in the normal control group. Therapy with ZnO-NPs led to a variable and significant decrease in albuminuria compared to the doxorubicin-treated group. While there was no significant change in albuminuria in the group treated with ZnONPs (10 mg/kg b.w./day) when compared with the normal control group, 3.8 Effect of ZnO-NPs on renal oxidative stress and antioxidant markers Renal MDA, SOD, CAT, and GSH were performed for evaluation of the renoprotective effect of ZnO-NPs (Figures 7 a–d) on doxorubicin treatment induced a highly significant increase in MDA and decreases in SOD, CAT, and GSH when compared to the normal control. While there was no significant change in MDA, SOD, CAT, or GSH in in group treated with ZnONPs (10 mg/kg b.w./day) when compared with the normal control group, Interestingly, the concentration of MDA was highly significant (P 0.001), while that of SOD, CAT, and GSH were significantly elevated (P 0.001) in the ZnO-NPs treated group when compared with the doxorubicin treated group. 3.9 Interleukin-6 (IL-6) levels in renal tissue of experimental groups. Renal IL-6 levels were significantly elevated in the doxorubicin-treated group compared to the normal control group. When compared to the doxorubicin-treated group, the ZnO-NPs (10 mg/kg b.w./day) group showed a highly significant decreased in renal IL-6 levels. While there was no significant change in renal IL-6 level in the group treated with ZnONPs (10 mg/kg b.w./day) when compared with the normal control group (Fig. 8), 4. Discussion DOX is used to treat multiple solid tumors but has severe adverse effects on the kidneys [33–35]. The mechanisms by which DOX causes glomerular toxicity are not yet fully understood. However, previous reports have shown that reactive oxygen species and free radicals are the most significant contributors to DOX-induced nephrotoxicity [35–37]. DOX exerts direct toxic damage to the glomerular base membrane, podocytes, and glomerular endothelial cells, inducing tubular interstitial inflammation and fibrosis [38]. Inflammation increases ROS production, oxidative stress, apoptosis, and a decrease in antioxidant enzymes in the kidney, all of which may be underlying causes of DOX-induced renal injury [39].As a result, renal function is compromised following DOX administration; in turn, serum urea and creatinine concentrations increase while serum albumin decreases, ultimately leading to extreme proteinuria [40]. Because rat intrarenal enzyme dissemination is similar to that of humans, drug-induced improvements in kidney function and tubular lesions can be easily evaluated [41].The current study was proposed to discern the potential of ZNONPS to prevent the chemotherapeutic drugs' induced renal toxicity, which might enhance the antitumor efficacy of DOX. In the current research, we used a cumulative dose of DOX injections to induce an experimental nephrotic syndrome model. This model was characterized by increased serum levels of creatinine and BUN (two significant indicators of renal function) and decreased serum albumin [42], as well as an elevated level of urine albumin (one of the general indicators of kidney injury) [43], all of which are associated with increased oxidative stress and inflammatory factors. The toxic effects of DOX administration observed in the current study are consistent with the findings of previous studies in which renal function parameters, including serum urea and creatinine, increased [44, 45]. However, administering ZnONPs before, during, and after DOX injections yielded improvements in renal function parameters, including decreased serum urea, increased creatinine, decreased urine albumin, and increased serum albumin. These improvements in DOX-induced renal dysfunction have been confirmed by histological and biochemical findings [46]. For example, DOX has been shown to increase oxidative stress in the kidneys, as indicated by changes in antioxidant status. The decline of SOD, CAT, and GR activities, accompanied by a decrement in GSH content, was unveiled after DOX injection, resulting in the reduced ability of the kidney to scavenge toxic H 2 O 2 and lipid peroxides. These findings were also noticed by other researchers [42]. In the present investigation, ZNONPS was able to significantly restore the above-mentioned antioxidant enzyme activities in kidney tissues. Reno-protective actions of ZNONPS against DOX-induced nephrotoxicity. Renal MDA was found to be increased after DOX inoculation, among other oxidative stress inducers. Outcomes of the present research also indicate that there was a significant increase in MDA and H2O2 quantity in the renal tissue of rats that received DOX alone in contrast to the control group. These results were in accord with preceding studies, which demonstrated an increase in lipid peroxidation and subsidence of the antioxidant defence system in the kidney after DOX treatment [47]. The findings show that ZNO-NPS can reverse renal injury caused by DOX treatments and confirm the importance of ZNO-NPS antioxidant properties in preventing drug-induced nephrotoxicity, specifically by enhancing the antioxidant defense system Consistently [47,48]. NF-kB is a transcription factor that regulates a wide variety of genes involved in developing renal disease [49, 50]. NF-kB activation plays a pivotal role in the pathogenesis of DOX-induced renal inflammation [51]. TNF-, IL-1, and IL-6 expression is mediated by NF-kB, which is responsible for inflammatory reactions [52, 53]. Furthermore, serum IL-6 levels were found to be higher in DOX-treated rats. The anti-inflammatory effects of ZnONPs have been described in multiple studies [54, 55, 56]. MinHo Kimet al. previously reported that ZnONPs had an anti-inflammatory effect by downregulating the expression of interleukin (IL)1, IL6, and TNF [44].Consistent with these observations, ZNO-NPS co-therapy reduced the extent to which IL-6 levels were altered by DOX. These results suggest that ZNO-NPS has anti-inflammatory effects and can reduce the harm done by DOX in harvested tissues. Dysregulation of inflammation and apoptosis is involved in DOX-induced renal injury. NF-B is involved in the signaling pathways of inflammation and apoptosis. It is reported that DOX could induce NF-B activation both in vivo and in vitro [57, 58]. However, little evidence is currently available on the relationship between DOX-induced cell apoptosis and NF-B activation. We examined the involvement of NF-B signaling molecules that have been implicated as stimulators of inflammation and apoptosis [59]. In our study, we observed that DOX-induced NF-B activation was prevented by ZNONPS. It was demonstrated that ZNONPS pretreatment decreased the expression of NF-B. Our results with ZNO-NPS show that ZNO-NPS reduces NF-B expression. The beneficial effects of ZnO-NPs were further illustrated by a histological evaluation using H&E staining, periodic acid Schiff (PAS), and Masson Trichrome. It was assumed that histopathological changes are related to the absorption capacity of renal tubules, which causes functional congestion of nephrons and subsequent kidney dysfunction [60].ZnONPs' treatment significantly ameliorates the damaging effects of DOX on kidney morphology. By acting as a potent quencher of radical species in the kidney, it prevents toxic influences at both the histological and biochemical levels [61]. These findings supported the hypothesis that ZnONPs could alleviate the biochemical and histological changes caused by DOX treatment. Therefore, ZnONPs might be a significant candidate, providing an excellent protective effect in combination with chemotherapy due to their antioxidant and radical species quenching potential. Our results suggest that ZNO-NPS alleviates DOX-induced nephrotic syndrome in rats, likely owing to its antioxidant and anti-inflammatory properties. These findings indicate that ZNO-NPS could be used as a therapeutic agent for DOX-induced nephrotoxicity. Conclusion The present study indicates that the treatment effect of ZnO-NPs on DOX provoked kidney damage in rats. The outcomes revealed the ameliorating potential of ZnO-NPs against DOX-induced kidney injury via suppression of the effect of DOX-mediated oxidative deterioration in renal tubular cells, preservation of kidney function biomarkers, and prevention of DNA damage. ZnO-NPs offered added protection against DOX-induced kidney damage. The mechanism of nephroprotective action of the ZnO-NPs fraction could be due to the antioxidant and free radical scavenging activities of its active metabolites. The present results suggest that ZnO-NPs might be potentially therapeutic in preventing the nephrotoxic and inflammatory effects of DOX. Declarations Acknowledgment The authors would like to thank the Chemistry Department, Faculty of Science, Mansoura University, Egypt for providing some of the facilities required during this study. They are also thankful for the faculty of Science, Suez Canal University, Egypt for providing facilities required for the study. Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Availability of data and materials: The data that supports this work is available upon reasonable request. Author Contributions: The study's inception and design were contributed to by all authors. Competing interests The authors declare no conflicts of interest. Funding No funding was received during the study. The study was done through self-finance. Authors' information 1 , Department of Chemistry, Faculty of Science, Suez Canal University, Ismailia, Egypt , 2 Biochemistry Division, Chemistry Department, Faculty of Science, Mansoura University, Mansoura, 35516, Egypt. *Corresponding author: Omali Y. El-Khawaga, Biochemistry Division, Chemistry Department, Faculty of Science, Mansoura University, Mansoura, 35516, Egypt. Email: [email protected] , +201028464738 References Siew ED, Davenport A. 2015. The growth of acute kidney injury: a rising Tide or just closer attention to detail? Kidney International, 87(1): 46–61. Tomino Y. 2014. Pathogenesis and treatment of chronic kidney disease: a Review of our recent basic and clinical data. Kidney & Blood Pressure Research, 39(5): 450–489. Chawla LS, Eggers PW, Star RA, Kimmel PL. 2014. Acute kidney injury and Chronic kidney disease as interconnected syndromes. The New England Journal of Medicine, 371(1): 58–66. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, et al; Acute Kidney Injury Network. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007;11:R31. Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl 2012;2:1-138. Hsu RK, Hsu CY. 2016. The role of acute kidney injury in chronic kidney Disease. Seminars in Nephrology, 36(4): 283–292. M. Cagel, E. Grotz, E. Bernabeu, M. A. Moretton, and D. A.Chiappetta, “Doxorubicin: nanotechnological overviews from bench to bedside,” Drug Discovery Today, vol. 22, no. 2 pp. 270–281, 2017. C. Carvalho, R. Santos, S. Cardoso et al., “Doxorubicin: the good, the bad and the ugly effect,” Current Medicinal Chemistry, vol. 16, no. 25, pp. 3267–3285, 2009 Shivakumar, P. ; M. U. Rani, A. G. Reddy, et al., 2012. A Study on the Toxic Effects of Doxorubicin on the Histology of Certain Organs, Toxicol. Int., 19(3), 241–244, Pubmed ID: 23293460. Sah, S. K. ; S. Khatiwada, D. Chaudhary, et al., 2015,Doxorubicin Induced Histomorphometric Changes in Testes of Albino Rats, Nepal J. Biotechnol., 3(1), 10–14, DOI: 10.3126/ njb.v3i1.14223. Wang YM, Wang Y, Harris DC, Alexander SI, Lee VW. Adriamycin nephropathy in BALB/c mice. Curr Protoc Im. 2015;108, 15.28.11-16. Yi M, Zhang L, Liu Y, et al. Autophagy is activated to protect against podocyte injury in adriamycin-induced nephropathy. Am J Physiol Ren Physiol. 2017;313:74e84. Lee VW, Harris DC. Adriamycin nephropathy: a model of focal segmental glomerulosclerosis. Nephrology (Carlton). 2011;16:30e38. Ava Soltani Hekmat, Ameneh Chenari, Hiva Alipanah and Kazem Javanmardi.:' Protective effect of alamandine on doxorubicin‑induced nephrotoxicity in rats', Soltani Hekmat et al. BMC Pharmacology and Toxicology, (2021), 22:31 Kantipudi, S., Sunkara, J.R., Rallabhandi, M., et al.: ‘Enhanced wound healing activity of Ag-ZnO composite NPs in Wistar albino rats’, IET Nanobiotechnol., 2018, 12, pp. 473–478 Shaaban, M., El-Mahdy, A.M.: ‘Biosynthesis of Ag, Se, and ZnO nanoparticles with antimicrobial activities against resistant pathogens using waste isolate Streptomyces enissocaesilis’, IET Nanobiotechnol., 2018, 12,pp. 741–747 Hongbo Shi , Ruth Magaye , Vincent Castranova and Jinshun Zhao. : 'Titanium dioxide nanoparticles: a review of current toxicological data' ,Particle and Fibre Toxicology 2013 10(1),15 Amira Awadalla a, Abdelaziz M. Hussein , Yousra M. El-Fard, Nashwa Barakat, Eman T. Hamam, Mohamed El-Sherbiny,f, Mohamed El-Shafey, Ahmed A. Shocker. :"Effect of zinc oxide nanoparticles and ferulic acid on renal ischemia/ reperfusion injury: possible underlying mechanisms," Biomedicine & Pharmacotherapy 140 (2021) 111686 [19] R.B. Gupta, U.B. Kompella, Nanoparticle technology for drug delivery. 2006. E.S. Ali, S.M. Sharker, M.T. Islam, I.N. Khan, S. Shaw, M.A. Rahman, et al., Targeting Cancer Cells With Nanotherapeutics and Nanodiagnostics: Current Status and Future Perspectives, Semin. Cancer Biol. (2020). [21] H. Najafzadeh, S. Ghoreishi, B. Mohammadian, E. Rahimi, M. Afzalzadeh, M. Kazemivarnamkhasti, H. Ganjealidarani, Serum biochemical and histopathological changes in liver and kidney in lambs after zinc oxide nanoparticles administration, Vet. World 6 (8) (2013) 534. [22] D. Dhawan, V.D. Chadha, Zinc: a promising agent in dietary chemoprevention of cancer, Indian J. Med. Res. (2010) 676. Yao, S. ; X. Feng, J. Lu et al., 2018 “Antibacterial activity and inflammation inhibition of ZnO nanoparticles embedded TiO2 nanotubes,” Nanotechnology, vol. 29, no. 24, article 244003,. P. Nagajyothi, S.J. Cha, I.J. Yang, T. Sreekanth, K.J. Kim, H.M. Shin, Antioxidant and anti-inflammatory activities of zinc oxide nanoparticles synthesized using Polygala tenuifolia root extract, J. Photochem. Photobiol. B Biol. 146 (2015) 10–17. [24] M. Afifi, A.M. Abdelazim, Ameliorative effect of zinc oxide and silver nanoparticles on antioxidant system in the brain of diabetic rats, Asian Pac. J. Trop. Biomed. 5 (10) (2015) 874–8 Yao, S. ; X. Feng, J. Lu et al., “Antibacterial activity and inflammation inhibition of ZnO nanoparticles embedded TiO2 nanotubes,” Nanotechnology, vol. 29, no. 24,2018, article 244003 Zeynab Khamis El-Maddawya and Walaa Slouma Hamouda Abd El Nab.: ' Protective effects of zinc oxide nanoparticles against doxorubicin induced testicular toxicity and DNA damage in male rats',Toxicol. Res., 2019, 8, 654–662 Mai Abdel Hamid Eita1,Rehab Hamdy Ashour,Omali Youssef El-Khawaga:. "Pentosan polysulfate exerts anti-inflammatory effect and halts albuminuria progression in diabetic nephropathy Role of combined losartan, "Fundam Clin Pharmacol. 2022;36:801–810 Tabacco A, Meiattini F, Moda E, Tarli P. Simplifiednenzymic/colorimetric serum urea nitrogen determination. Clin Chem. 1979;25(2):336-337. doi:10.1093/clinchem/25.2.336a B. T. Doumas, T. Peters," Serum and urine albumin: a progress report on their measurement and clinical significance", Clin. Chim. Acta 1997, 258(1), 3–20. doi.org/10.1016/S0009-8981(96)06447-9 Schosinsky KH, Vargas M, Luz Esquivel A, Chavarria MA. Simple spectrophotometric determination of urinary albumin by dyebinding with use of bromphenol blue. Clin Chem. 1987;33(2 Pt. Ava Soltani Hekmat, Ameneh Chenari, Hiva Alipanah and Kazem Javanmardi" ,Protective effect of alamandine on Doxorubicin‑induced nephrotoxicity in rats ,"BMC Pharmacology and Toxicology (2021) 22:31 Bancroft, J.D., Stevens, A.: ‘Theory and practice of histological techniques’(Churchill Livingstone, Edinburgh, 1990, 3rd edn.) Ava Soltani Hekmat, Ameneh Chenari, Hiva Alipanah and Kazem Javanmardi" ,Protective effect of alamandine on Doxorubicin‑induced nephrotoxicity in rats ,"BMC Pharmacology and Toxicology (2021) 22:31 Saad SY, Najjar TA, Al-Rikabi AC. The preventive role of deferoxamine against acute doxorubicin-induced cardiac, renal and hepatic toxicity in rats. Pharmacol Res. 2001;43(3):211–8. Hussain MA, Abogresha NM, AbdelKader G, Hassan R, Abdelaziz EZ, Greish SM. Antioxidant and Anti-Inflammatory Effects of Crocin Ameliorate Doxorubicin-Induced Nephrotoxicity in Rats. Oxid Med Cell Longev. 2021; .2021:8841726 Liu LL, Li QX, Xia L, Li J, Shao L. Differential effects of dihydropyridine calcium antagonists on doxorubicin-induced nephrotoxicity in rats. Toxicology. 2007;231(1):81–90. [37]. De Beer EL, Bottone AE, Voest EE. Doxorubicin and mechanical performance of cardiac trabeculae after acute and chronic treatment: A review. Eur J Pharmacol. 2001;415(1):1–11. Jeansson M, Björck K, Tenstad O, Haraldsson B. Adriamycin alters glomerular endothelium to induce proteinuria. J Am Soc Nephrol. 2009;20(1):114–22. Tayyaba Afsar, Suhail Razak , Ali Almajwal, Dara Al-Disi," Doxorubicin-induced alterations in kidney functioning, oxidative stress,DNA damage, and renal tissue morphology; Improvement by Acacia hydaspica tannin-rich ethyl acetate fraction",T. Afsar et al. / Saudi Journal of Biological Sciences 27 (2020) 2251–2260. Wu Q, Li W, Zhao J, Sun W, Yang Q, Chen C, et al. Apigenin ameliorates doxorubicin-induced renal injury via inhibition of oxidative stress and inflammation. Biomed Pharmacother. 2021;137:111308. [41] Saad, A.A., Youssef, M.I., El-Shennawy, L.K., 2009. Cisplatin induced damage in kidney genomic DNA and nephrotoxicity in male rats: the protective effect of grape seed proanthocyanidin extract. Food Chem. Toxicol. 47, 1499–1506. El-Sheikh, A.A., Morsy, M.A., Mahmoud, M.M., Rifaai, R.A., Abdelrahman, A.M., 2012. Effect of coenzyme-Q10 on doxorubicin-induced nephrotoxicity in rats. Adv. Pharm. Sci. Dhondup, T., Qian, Q., 2017. Electrolyte and acid-base disorders in chronic kidney disease and end-stage kidney failure. Blood Purificat. 43, 179–188. Koul A, Shubrant, Gupta P. Phytomodulatory potential of lycopene from Lycopersicum esculentum against doxorubicin induced nephrotoxicity. Indian J Exp Biol. 2013;51(8):635–45. Mancilla TR, Iskra B, Aune GJ. Doxorubicin-induced cardiomyopathy in Children. Compr Physiol. 2019 ;9(3):905–931. Lamiaa A.A. Barakata, Nashwa Barakatb, Mahmoud M. Zakariab, Salma M. Khirallaha," Protective role of zinc oxide nanoparticles in kidney injury induced by cisplatin in rats" Life Sciences 262 (2020) 118503. Azza A. K. El-Sheikh,Mohamed A. Morsy, Marwa M. Mahmoud,Rehab A. Rifaai, and Aly M. Abdelrahman" Effect of Coenzyme-Q10 on Doxorubicin-Induced Nephrotoxicity in Rats, Volume 2012, Article ID 981461, 8 pages. Amira Awadalla, Abdelaziz M. Hussein , Yousra M. El-Fard, Nashwa Barakat, Eman T. Hamama, Mohamed El-Sherbinye, Mohamed El-Shafey, Ahmed A. Shokei " ,rEffect of zinc oxide nanoparticles and ferulic acid on renal ischemia/ reperfusion injury: possible underlying mechanisms"Biomedicine & Pharmacotherapy 140 (2021) 111686. [49] Sanz AB, Sanchez-Niño MD, Ramos AM, Moreno JA, Santamaria B, RuizOrtega M, et al. NF-κB in renal inflammation. J Am Soc Nephrol. 2010;21(8): 1254–62. Aboyoussef AM, Abdel-Sattar AR, Abdel-Bakky MS, Messiha BAS. Enoxaparin prevents CXCL16/ADAM10-mediated cisplatin renal toxicity: Role of the coagulation system and the transcriptional factor NF-κB. Life Sci. 2021;270:119120. Sutariya B, Saraf M. α-asarone reduce proteinuria by restoring antioxidant enzymes activities and regulating necrosis factor κB signaling pathway in doxorubicin-induced nephrotic syndrome. Biomed Pharmacother. 2018;98:318–324. Vyas D, Laput G, Vyas AK. Chemotherapy-enhanced inflammation may lead to the failure of therapy and metastasis. OncoTargets and Therapy. 2014;7:1015–23. Somade OT, Ajayi BO, Safiriyu OA, Oyabunmi OS, Akamo AJ. Renal and testicular up-regulation of pro-inflammatory chemokines (RANTES and CCL2) and cytokines (TNF-α, IL-1β, IL-6) following acute edible camphor administration is through activation of NF-kB in rats. Toxicol Reports. 2019;6:759–767. Nagajyothi, P., et al.: Antioxidant and anti‐inflammatory activities of zinc oxide nanoparticles synthesised using polygala tenuifolia root extract. J. Photoch. Photobio. B. 146, 10–17 (2015) Kim, M.H., et al.: Zinc oxide nanoparticles, a novel candidate for the treatment of allergic inflammatory diseases. Eur. J. Pharmacol. 738,31–39 (2014) [56]Adamcakova‐Dodd, A., et al.: Toxicity assessment of zinc oxide nanoparticles using sub‐acute and sub‐chronic murine inhalation models. Part. Fibre Toxicol. 11(1), 15 (2014) Rasha E. Mostafa, Dalia O. Saleh, Dina F. Mansour",Cisplatin-Induced Nephrotoxicity in Rats: Modulatory Role of Simvastatin and Rosuvastatin against Apoptosis and Inflammation" ,Journal of Applied Pharmaceutical Science Vol. 8(04), pp 043-050, April, 2018 Davoud Sanajou & Saeed Nazari Soltan Ahmad & Vahid Hosseini & Ashkan Kalantary-Charvadeh &Yasser Marandi & Leila Roshangar & Saman Bahrambeigi & Mehran Mesgari-Abbasi", β-Lapachone protects against doxorubicin-induced nephrotoxicity via NAD+/AMPK/NF-kB in mice",Naunyn-Schmiedeberg's Archives of Pharmacology (2019) 392:633–640. Wang S, Kotamraju S, Konorev E, Kalivendi S, Joseph J, Kalyanaraman B. Activation of nuclear factor-κB during doxorubicin-induced apoptosis in endothelial cells and myocytes is pro-apoptotic: The role of hydrogen peroxide. Biochem J. 2002;367(Pt 3):729–40 Khan, R.A., Khan, M.R., Sahreen, S., 2012. Protective effects of rutin against potassium bromate induced nephrotoxicity in rats. BMC Complement. Alternative Med. 12, 204. Shahbazi, F., Dashti-Khavidaki, S., Khalili, H., Lessan-Pezeshki, M., 2012. Potential renoprotective effects of silymarin against nephrotoxic drugs: a review of literature. J. Pharm. Pharm. Sci. 15, 112–123. Additional Declarations No competing interests reported. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-2814493","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":191765809,"identity":"624beef1-de59-4b89-bd07-e090f26d507a","order_by":0,"name":"Ahlam Elgohary","email":"","orcid":"","institution":"Mansoura University","correspondingAuthor":false,"prefix":"","firstName":"Ahlam","middleName":"","lastName":"Elgohary","suffix":""},{"id":191765810,"identity":"e936780d-99a3-4fff-8296-f8a9597bbdcd","order_by":1,"name":"Faten Metwalli","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Faten","middleName":"","lastName":"Metwalli","suffix":""},{"id":191765811,"identity":"9bb94a93-44ec-437c-bae0-557be20020e7","order_by":2,"name":"Nasser Mostafa","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Nasser","middleName":"","lastName":"Mostafa","suffix":""},{"id":191765812,"identity":"cedaec1b-7f74-470c-8a3c-5e736c6609c2","order_by":3,"name":"Manar reffat","email":"","orcid":"","institution":"Mansoura University","correspondingAuthor":false,"prefix":"","firstName":"Manar","middleName":"","lastName":"reffat","suffix":""},{"id":191765813,"identity":"3a9ededa-188e-4b0c-9e0b-dd31c71722b4","order_by":4,"name":"Omali El-Khawaga","email":"data:image/png;base64,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","orcid":"","institution":"Mansoura University","correspondingAuthor":true,"prefix":"","firstName":"Omali","middleName":"","lastName":"El-Khawaga","suffix":""}],"badges":[],"createdAt":"2023-04-13 20:59:16","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-2814493/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-2814493/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":35878046,"identity":"9dfa7ae1-5e68-44b9-bbfa-9eb0e220e74a","added_by":"auto","created_at":"2023-04-17 14:37:21","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":113280,"visible":true,"origin":"","legend":"\u003cp\u003eXRD pattern of ZnO nanoparticles\u003c/p\u003e","description":"","filename":"1.png","url":"https://assets-eu.researchsquare.com/files/rs-2814493/v1/dd7ad801cadb72754bbaba63.png"},{"id":35878045,"identity":"d9a6cd63-d2c8-4b6f-8ba5-66e7e3cb0ab8","added_by":"auto","created_at":"2023-04-17 14:37:20","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":207147,"visible":true,"origin":"","legend":"\u003cp\u003e(a) SEM image of prepared ZnONPs \u0026nbsp;and (b) EDX analysis\u003c/p\u003e","description":"","filename":"2.png","url":"https://assets-eu.researchsquare.com/files/rs-2814493/v1/7fc393eaa6e31a3e3607e1cc.png"},{"id":35879350,"identity":"9dac15c2-d44a-4feb-a19d-ede796e46997","added_by":"auto","created_at":"2023-04-17 14:45:20","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":135026,"visible":true,"origin":"","legend":"\u003cp\u003eTEM image of prepared ZnONPs\u003c/p\u003e","description":"","filename":"3.png","url":"https://assets-eu.researchsquare.com/files/rs-2814493/v1/2d6b1ce90aad2d0ed92c8d20.png"},{"id":35878040,"identity":"2d23d927-ccd2-4d1f-b000-e9ffb190c161","added_by":"auto","created_at":"2023-04-17 14:37:20","extension":"png","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":49158,"visible":true,"origin":"","legend":"\u003cp\u003esize distribution of ZNO-NPS\u003c/p\u003e","description":"","filename":"4.png","url":"https://assets-eu.researchsquare.com/files/rs-2814493/v1/14719117912154fbeb404f07.png"},{"id":35878044,"identity":"2cccc3e9-da59-49cf-a53a-e3f6afb0b836","added_by":"auto","created_at":"2023-04-17 14:37:20","extension":"png","order_by":5,"title":"Figure 5","display":"","copyAsset":false,"role":"figure","size":62732,"visible":true,"origin":"","legend":"\u003cp\u003ezeta potential of ZnO-NPs\u003c/p\u003e","description":"","filename":"5.png","url":"https://assets-eu.researchsquare.com/files/rs-2814493/v1/724c30ceafae55ccc82216c8.png"},{"id":35879351,"identity":"524477d6-dcfb-4cac-aa66-3e309180ba6e","added_by":"auto","created_at":"2023-04-17 14:45:20","extension":"png","order_by":6,"title":"Figure 6","display":"","copyAsset":false,"role":"figure","size":48310,"visible":true,"origin":"","legend":"\u003cp\u003eEffect of ZnO-NPs on albuminuria against Doxorubicin-induced nephrotoxicity.\u003c/p\u003e\n\u003cp\u003eValues are expressed as mean ± SEM (n =9–10/group); statistics were done using one-way, ANOVA followed by post hoc Tukey test (Pvalue ≤ 0.05).\u003c/p\u003e","description":"","filename":"6.png","url":"https://assets-eu.researchsquare.com/files/rs-2814493/v1/499353df7186477e42171a18.png"},{"id":35878043,"identity":"f90afb54-b881-4f6f-9de4-8742ddedcf70","added_by":"auto","created_at":"2023-04-17 14:37:20","extension":"png","order_by":7,"title":"Figure 7","display":"","copyAsset":false,"role":"figure","size":120163,"visible":true,"origin":"","legend":"\u003cp\u003eThe effects of DOX and/or ZnONPs on the oxidative stress of renal tissues of different groups: \u0026nbsp;(a) renal malondialdehyde levels (MDA), (b) renal superoxide dismutase activity (SOD), (C) renal catalase activity (CAT)and (d)renal glutathione-S-transferase activity(GSH). Values are expressed as mean ± SEM ; statistics were done using one-way ANOVA followed by Post Hoc Tukey test( P value≤0.05) .\u003c/p\u003e","description":"","filename":"7.png","url":"https://assets-eu.researchsquare.com/files/rs-2814493/v1/64401765c407c78a596ad62a.png"},{"id":35878048,"identity":"e47ee0d5-ebd8-4add-990b-e69ab18533b4","added_by":"auto","created_at":"2023-04-17 14:37:21","extension":"png","order_by":8,"title":"Figure 8","display":"","copyAsset":false,"role":"figure","size":69857,"visible":true,"origin":"","legend":"\u003cp\u003eThe effects of DOX and/or ZnONPs on interleukin-6 (IL-6) of renal tissues of different groups Values are expressed as mean ± SEM\u003c/p\u003e","description":"","filename":"8.png","url":"https://assets-eu.researchsquare.com/files/rs-2814493/v1/6ac55593854ea1a4e80ad383.png"},{"id":35879352,"identity":"62dc915f-249e-4c3f-998a-2aa477982efa","added_by":"auto","created_at":"2023-04-17 14:45:20","extension":"png","order_by":9,"title":"Figure 9","display":"","copyAsset":false,"role":"figure","size":854540,"visible":true,"origin":"","legend":"\u003cp\u003eRepresentative photomicrograph of morphological changes in the kidney of studied groups stained with: \u003cstrong\u003eA: H \u0026amp; E stained\u003c/strong\u003e of different kidney samples (a, b) (a, b) demonstrating normal cortex and medulla with minimal interstitial tissue, (c) demonstrating severe pathological changes including: dilated Bowman's capsule with thickened glomerular basement membrane (thick black arrows), mononuclear cells infiltration in interstitial tissue (yellow arrow), congestion, interstitial fibrosis, tubular cast formation, and Endothelial cell swelling (d) with milder pathological changes such as dilated Bowman's capsule (thick black arrows), mild interstitial congestion (red arrows), and few mononuclear cells infiltration\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eB: Periodic acid-Schiff (PAS) stain\u003c/strong\u003e displayed glycogen deposition (magenta-purple color) within the cortex and medulla of different kidney treated samples (a, b) showed normal glycogen deposition; (c) showed strongly depleted glycogen deposition in the glomerular tuft (black arrowheads), glomerular (thin black arrows), tubular basement membranes, and interstitial tissue (blue arrows).In addition to tubular lumen, group (d) showed a significant decrease in glycogen depletion and tubular degeneration. \u003cstrong\u003eC: Masson Trichrome (MT) stain\u003c/strong\u003e demonstrated collagen deposition in cortex and medulla (a, b) and exhibited the normal appearance of glomeruli and an intact Bowman’s capsule (c); it displayed excess blue-stained collagen deposition in interstitial tissue in both cortex and medulla, indicating induced fibroplasia (black arrows); and it displayed very mild blue-stained collagen deposition in interstitial tissue. \u003cstrong\u003eD: immunostaining for NF-kB expression\u003c/strong\u003e in the kidney of the studied groups (a, b) showed almost negative NF-kB expression in tubular cells with brown-colored staining in the renal cortex tissue, (c) showed marked positive brown staining of many tubules (black arrows) , (d) The positive staining markedly decreased in the kidney samples of the group of DOX treated with ZnO-NPs referring to a significant drop in the inflammation profile. \u003cstrong\u003eN: Normal control\u003c/strong\u003e\u003c/p\u003e","description":"","filename":"9.png","url":"https://assets-eu.researchsquare.com/files/rs-2814493/v1/cd59c90bc2757da2d4da6330.png"},{"id":35880253,"identity":"9f44200b-cbc1-4493-8415-ca3ef177e625","added_by":"auto","created_at":"2023-04-17 14:53:26","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":2571505,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-2814493/v1/89cbe481-32e3-4746-be2a-ee75397d5499.pdf"},{"id":35880252,"identity":"a9e970d5-e136-4374-a0b2-05cb6b1c1c38","added_by":"auto","created_at":"2023-04-17 14:53:26","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":2571505,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-2814493/v1/33f4328a-2ca0-45ac-b721-96e272c06fe9.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"Zinc oxide nanoparticles regulate NF-kB expression and restrict inflammation response in Doxorubicin- induced kidney injury in rats","fulltext":[{"header":"1. Introduction","content":"\u003cp\u003eAcute kidney injury (AKI) and chronic kidney disease (CKD) are linked to high morbidity and mortality. AKI is regarded as a rapid and reversible decline in renal function and is associated with accelerated CKD [1]. CKD is a significant medical problem globally, with a rapid increase in incidence due to the rise in hypertension and diabetes [2]. CKD also plays an important role in AKI. Patients with CKD are more likely to experience transient decreases in renal function consistent with AKI [3]. Furthermore, the syndrome is quite common among patients without a critical illness, and it is essential that health care professionals, particularly those without specialization in renal disorders, detect it easily. The classification of AKI includes pre-renal AKI, acute post-renal obstructive nephropathy, and intrinsic acute kidney diseases. Of these, only \u0026quot;intrinsic\u0026quot; AKI represents true kidney disease, while pre-renal and post-renal AKI are the consequence of extra-renal diseases leading to a decreased glomerular filtration rate (GFR). If these pre- and/or post-renal conditions continue, they will lead to renal cellular damage and, as a result, intrinsic renal disease [4,5]. The underlying mechanisms that result in acute renal dysfunction may involve decreased GFR, increased proteinuria, renal autoregulation failure, and drug-induced nephrotoxicity [6].\u003c/p\u003e\n\u003cp\u003eDoxorubicin (DOX), which is a member of the anthracycline family of cytotoxic antibiotics and one of the most potent and commonly used chemotherapeutic agents for the treatment of various types of cancer [7], The antitumor activity of doxorubicin is attributed to its ability to intercalate into the DNA helix and/or bind covalently to proteins involved in DNA replication and transcription, resulting in inhibition of DNA, RNA, and protein synthesis, leading finally to cell death [8]. Doxorubicin-based chemotherapy for the treatment of a wide spectrum of both hematological and solid tumors It is also associated with toxicities to different organs like the heart, kidney, liver, and testis [9]. The exact mechanism of DOX-induced nephrotoxicity is not yet known. Furthermore, it has been suggested by many investigators that DOX can induce the generation of reactive oxygen species (ROS), which cause damage to membranes and macromolecules through lipid peroxidation, oxidative stress, DNA fragmentation, and protein oxidation [10]. The increase in oxidative stress and depletion of endogenous antioxidants trigger the apoptotic pathway in the kidney [11, 12]. Available laboratory evidence shows that DOX induces nephropathy via its detrimental effects on renal tissue, including increased glomerular capillary permeability and glomerular atrophy, and accumulation of DOX in the glomerulus [13]. Therefore, administering drugs with anti-inflammatory and antioxidant effects could mitigate the side effects of DOX [14].\u003c/p\u003e\n\u003cp\u003eNowadays, nanoparticles are primarily the most important aspect of nanotechnology because of their economic and commercial significance. Recent studies have shown the role of metals in life-threatening diseases [15, 16]. Nanoparticles are used in a variety of preclinical and clinical applications due to their unique properties, such as cellular uptake and delivery efficiency to biological systems. In the nanoscale dimension, nanoparticles (NPs) have different catalytic properties than larger particles of the same composition [17].\u003c/p\u003e\n\u003cp\u003eNanoparticles, particles with a diameter less than 50 nm, have a lot of applications, including as drug carriers, which are important in the management of several disorders [18, 19].. Zinc oxide nanoparticles (ZnO-NPs) are one of the important nanoparticles that are commonly used in sunscreens, biosensors, pigments, food additives, and medicine [20]. Although several studies reported that ZnO-NPs have cytotoxic effects [21], other studies reported that they have antioxidant effects [22] and antibacterial effects [23]. Furthermore, ZnO-NPs inhibit the expression of several cytokines at the mRNA and protein levels, including IL6, IL-1, iNOS, COX-2, and TNF- [23]. Furthermore, it has anti-diabetic properties, as ZnO-NPs reduce oxidative stress in diabetic rats [24]. Due to the inherent toxicity of ZnO NPs, they possess strong inhibitory effects against cancerous cells and bacteria by inducing intracellular ROS generation and activating the apoptotic signaling pathway, which makes ZnO NPs a potential candidate as anticancer and antibacterial agents [25]. Although many studies have shown that ZnO-NPs have cytoprotective effects in various tissues [22-24], To the best of our knowledge, the effect of ZnO-NPs against renal IRI is the first one. Thus, the current study was designed to examine the effect of ZnO-NPs on renal I/R injury status and antioxidant profile. Then, we explored the effects on the expression of immune nuclear factor-kappa B (NF-B) and interleukin-6 (IL-6) and kidney function in addition to the histopathological picture of the kidney. This is all to provide evidence that will support therapeutic efforts to treat renal I/R injury with ZnONPs.\u003c/p\u003e"},{"header":"2. Material And Methods","content":"\u003cp\u003e\u003cstrong\u003e2.1 Preparation of Dispersible ZnO Nanoparticles ( ZnONPs):\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eZnO nanoparticles were produced as follows: 40 mmoles of zinc sulphate (ZnSO4) and 40 mmoles of urea (CO(NH\u003csub\u003e2\u003c/sub\u003e)\u003csub\u003e2\u003c/sub\u003e) were dissolved in 1 litre of deionized water with vigorous stirring. A 3.0 M sodium hydroxide (NaOH) solution was added while stirring until the pH reached 12. The stirring continued for 30 minutes at room temperature. The solution was transported into a Teflon container open to the atmosphere and heated in microwave oven (2.45 GHz) at 800 watts of power for 10 minutes. After cooling to room temperature, the produced ZnO nanoparticles were centrifuged and washed with deionized water. Part of the ZnO nanoparticles were dried at 95 \u0026deg;C for XRD analysis, and the remaining part was dispersed in deionized water and kept in the refrigerator for use. According to Torabi et al. [26], ZnO NPs were then suspended in saline (0.9%) before use. and dispersed by ultrasonication to avoid particle aggregation.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e2.2 Characterization of ZnONPs\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eIn the present study, the average particle size of nano-ZnO was less than 50 nm. X-ray diffraction (XRD) was used to determine the nature and size of ZnO crystalline phases. To confirm the size and determine the morphology and crystalline quality, nano-ZnO was investigated in detail via TEM (Tecnai G2 20 STWIN, Philips, Netherlands), and ZnO particle sizes were examined by scanning electron microscope (SEM, Hitachi S4800). Particles\u0026rsquo; size and zeta potential were measured using dynamic light scattering (DLS, Zetasizer 5000, Malvern, Worcestershire, U.K.).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e2.3 Experimental animals\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe present study included Fifty adult male albino rats aging 6 weeks, with an average body weight of 100 to120 g purchased from Holding Company for Biological Products and Vaccines, Cairo, Egypt. The rats were housed in groups in \u0026nbsp;metal cages for bedding \u0026nbsp;on a standard rat pellet diet and tap water adlabitum under controlled conditional of temperature (23.0\u0026plusmn;1.0 C\u0026deg;) and humidity at 55\u0026plusmn;10%with a 12 h light/dark cycle respectively for one week before and during the experiment. Animal treatments in this study were performed in compliance with the guidelines of the Guide for the Care and Use of Laboratory Animals and approved by Mansoura University animal care committee.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;2.4 Animal grouping:\u0026nbsp;\u003c/strong\u003eExperimental design\u003c/p\u003e\n\u003cp\u003eAfter an acclimatization period of one week, the rats were randomly distributed into five equal groups (n = 10). The experimental study period was four weeks, and the studied groups were as follows: In the control\u003cstrong\u003e\u0026nbsp;group\u0026nbsp;\u003c/strong\u003e(\u003cstrong\u003eCNT group),\u003c/strong\u003e the rats were intraperitoneally (IP) injected with three equal injections at 4-day intervals over a period of two weeks, starting on the first day of the second week, with 500 l \u0026micro;l \u0026nbsp;physiological saline. The rats in the \u003cstrong\u003enephrotoxic control group (DOX treated)\u0026nbsp;\u003c/strong\u003ewere IP injected three times at four-day intervals for two weeks, beginning on the first day of the second week, with 500 l of DOX dissolved in physiological saline at a dose of 5 mg/kg BW, for a total cumulative dose of 15 mg/kg BW. \u003cstrong\u003eZnONP\u0026apos;s normal treated group,\u0026nbsp;\u003c/strong\u003eThe rats were administered with 200 l of ZnONPs solution, respectively, at a dose of 10 mg/kg BW, through IP (injected every day over a period of two weeks). \u003cstrong\u003eThe nephrotoxic group was treated with ZnONPs (DOX-ZNONPs group)\u003c/strong\u003e, and the rats were given both DOX (as mentioned in the DOX group) at 5 mg/kg BW and 200 l of ZnONPs dissolved in physiological saline, respectively, at a dose of 10 mg/kg BW via IP, injected every day for two weeks (two weeks after DOX injection).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e2.5 Collection of urine samples\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eUrine samples were collected from all rats in each group, which were individually housed in metabolic cages to allow for 24-hour urine collection. Rats continued to have free access to water and a standard diet. Total urine volume was measured; 1 ml was collected from a 24-hour urine sample, stored at -80 \u0026deg;C, and used for the determination of urinary albumin excretion.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;2.6 Biochemical assessment\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eBlood samples were collected for measurement of creatinine using creatinine kits, Jaff\u0026eacute;, colorimetric method\u0026mdash;end point (Diamond Diagnostics Company, Hannover, Germany) according to manufacture instruction [27]; blood urea nitrogen (BUN) using urea kits, Berthelot enzymatic colorimetric method (Diamond Diagnostics Company, Hannover, Germany) according to manufacture instruction [28]; and albumin, ALT, and AST were measured spectrophotometrically in serum using biodiagnostic kits (BioMed Diagnostics Company, Badr, Egypt) according to manufacture instruction [29]; and Urinary albumin excretion (g/mL) was also measured using microalbuminuria kits (ABC Diagnostic, New Damietta, Egypt) and a rapid colorimetric method according to the manufacturer\u0026apos;s instructions [30] Albuminuria was calculated as g/24 h by taking the urine volume (ml) in 24 hours into account.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e2.7 Assessment of oxidative stress and inflammatory markers\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe right kidney of all rats was collected and homogenized in phosphate buffer (pH 7.4) to assess the level of oxidative stress markers (malondialdehyde \u0026quot;MDA,\u0026quot; \u0026nbsp;reduced glutathione \u0026quot;GSH,\u0026quot; \u0026nbsp;catalase \u0026quot;CA,\u0026quot; \u0026nbsp;and superoxide dismutase \u0026quot;SOD\u0026quot;) and the inflammatory marker \u0026quot;IL-6\u0026quot; using specific kits according to the manufacturer\u0026apos;s instructions. Kits for MDA (Cat. No. MD 25-29), GSH (Cat. No. GR 25-11), CA (Cat. No. CA 25-17), and SOD (Cat. No. SD 25-21) were purchased from the Bio-Diagnostic Company, Giza, Egypt; a rat IL-6 ELISA kit was purchased from the Bioassay Technology Laboratory Company (Cat. No. E0135Ra Shanghai, China).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e2.8 Immunohistochemistry (IHC\u003cspan dir=\"RTL\"\u003e(\u003c/span\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;NF-B expression was evaluated on paraffin-embedded tissues by a standard immunostaining assay. Briefly, xylene and a graded alcohol series were used for deparaffinization and rehydration, respectively. Then the slides were incubated for 30 minutes in a blocking reagent containing 1.5 percent hydrogen peroxide in methanol. Antigens were retrieved and placed on slides using a microwave protocol. They were then incubated in serum for 30 min and immunostained with NF-B (cat. no. sc-48,366; Santa Cruz Biotechnology, Inc.) primary antibodies for 1 h at room temperature. Afterward, the slides were washed with PBS three times and then incubated with secondary antibodies for 30 min. The sections were stained using 3,30-diaminobenzidine (Dako liquid DAB color solution), and the slides were then counterstained with hematoxylin. An Olympus BX51 microscope (Olympus, Tokyo, Japan) was used to visualize the results. Five different microscopic fields were randomly selected from each slide, and positive staining within each slide was measured using Image-Pro Plus 6.1. Finally, quantitative analysis was performed in a blinded manner [31].\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e2.9 Histopathological assessment\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAll rats\u0026apos; left kidneys were perfused with neutral buffered formalin (10%) and processed in 5 m paraffin sections for histopathological examination. All kidney tissues were stained with hematoxylin and eosin (H\u0026amp;E), periodic acid Schiff (PAS), and Masson Trichrome. Changes in kidney structure were analyzed to assess the severity of the morphologic changes (glomerulosclerosis, interstitial inflammation, interstitial fibrosis tubular atrophy, \u0026quot;IFTA,\u0026quot; and vascular lesions), and then each type of lesion was graded semi-quantitatively as described previously [32].\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e2.10 Statistical analysis\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eData analysis was expressed as mean \u0026plusmn; SEM. Difference between groups was detected using one way ANOVA followed with post Hoc Tukey test using SPSS software version 21 . Values at P \u0026lt; 0.05 were considered statically significant.\u003c/p\u003e"},{"header":"3. Results","content":"\u003cp\u003e\u003cstrong\u003e3.1 \u0026nbsp;XRD analysis of ZnO-NPs\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe phase of the as-synthesized ZnO products was determined using XRD, as shown in Fig. 1. XRD analysis reveals that the sample is a pure ZnO phase of the hexagonal ZnO phase (wurtzite-type structure, space group: P63mc (186). All the diffraction peaks were indexed to the (100), (002), (101), (102), (110), (103), (200), and (211) planes of the pure hexagonal wurtzite structure. No impurities were detected in these products.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e3.2 SEM microstructure analysis\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe morphology of the samples was investigated using SEM. Figure 2 (a) shows the SEM micrographs. The SEM images show that \u0026nbsp;the samples were agglomerated to some extent, and have an irregular spherical shape with a particle size The composition of the samples is determined using the EDX spectra obtained in conjunction with the SEM micrographs. Figure 2 (b) depicts the resulting EDX spectrum, where Zn and O peaks are clearly seen without any other peaks bearing any resemblance to other elements.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e3.3 TEM analysis of ZnONPs\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe TEM observations illustrated that ZnONPs exhibited almost spherical \u0026nbsp;Geometry with diameter about 30-50nm. \u0026nbsp;(Fig. 3)\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e3.4 Detection of particle size analysis :\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe size distribution was determined by dynamic light scattering (DLS). They had a good dispersion, which is in good agreement with the DLS result shown in Fig 4.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e3.5 zeta potential measurements:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe zeta potentials of the synthesized NPs were detected from their electrophoretic mobilities using Microtrac and Nanotrac Wave II Q, and the zeta potential of the particles was -16.1 mV, which is of good quality, and Z-Average (d.nm.): 1239, as shown in Fig 5.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e3. 6 Effects of ZnO-NPs \u0026nbsp;on kidney and liver functions of experimental groups\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe treatment effect of ZnO-NPs on kidney dysfunction induced by doxorubicin \u0026nbsp;is presented in Table1 and indicated by analyzing serum creatinine, BUN , albumin, AST and ALT. In doxorubicin treated \u0026nbsp;group, \u0026nbsp; serum creatinine, BUN were a highly significant increase when compared with the normal control group. While treated group with ZnO-NPs (10 mg/kg b.w./day) showed a highly significant reduction in serum creatinine, BUN levels when compared with the doxorubicin treated \u0026nbsp; group (Table 1).While there was no significant change in serum creatinine, BUN levels in group treated withZnONPs \u0026nbsp;( 10 mg/kg b.w./day) when compared with the normal control group. There was \u0026nbsp;a highly significant decrease \u0026nbsp;in serum albumin level \u0026nbsp;in doxorubicin treated \u0026nbsp;group when compared with the normal control group(Table 1).While there was no significant change in serum albumin level in group treated with ZnONPs (10 mg/kg b.w./day) when compared with the normal control group. While there was ahighly significant increase in serum albumin level in treatment group with ZnO-NPs (10 mg/kg b.w./day when compared with the doxorubicin treated \u0026nbsp;group (Table 1). Moreover, the effect of DOX resulted in a highly significant increase in serum AST and ALT levels compared to the normal control group. While there was no significant change in serum AST and ALT levels in the group treated with ZnONPs (10 mg/kg b.w./day) when compared to the normal control group, While there was a highly significant decrease in serum AST and ALT levels in the treatment group with ZnO-NPs (10 mg/kg b.w./day) when compared with the doxorubicin-treated group,\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable1:\u0026nbsp;\u003c/strong\u003eThe effects of DOX and/or ZnONPs \u0026nbsp;on and Liver functions of experimental groups\u003c/p\u003e\n\u003cp\u003e\u003cimg src=\"data:image/png;base64,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\" width=\"814\" height=\"447\"\u003e\u003c/p\u003e\n\u003cp\u003eNote: Values are expressed as mean\u0026plusmn;SEM ; statistics were done using one-way ANOVA followed by Post Hoc Tukey test \u003cspan dir=\"RTL\"\u003e)\u003c/span\u003e P value\u0026le;0.05\u003cspan dir=\"RTL\"\u003e(\u003c/span\u003e .\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ea\u0026nbsp;\u003c/sup\u003eHighly significant in comparison with normal control group \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003csup\u003eb\u003c/sup\u003eHighly significant in comparison with doxorubicin treated group ; NS, not significant\u003c/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e3.7 Effects of ZnO-NPs \u0026nbsp;on Albuminuria of experimental groups\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eFigure 6 shows the serial changes of albuminuria (g/24 h) in the experimental groups. Albuminuria was significantly higher in the doxorubicin-treated group than in the normal control group. Therapy with ZnO-NPs led to a variable and significant decrease in albuminuria compared to the doxorubicin-treated group. While there was no significant change in albuminuria in the group treated with ZnONPs (10 mg/kg b.w./day) when compared with the normal control group,\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e3.8 Effect of ZnO-NPs on renal oxidative stress and antioxidant markers\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eRenal MDA, SOD, CAT, and GSH were performed for evaluation of the renoprotective effect of ZnO-NPs (Figures 7 a\u0026ndash;d) on doxorubicin treatment induced a highly significant increase in MDA and decreases in SOD, CAT, and GSH when compared to the normal control. While there was no significant change in MDA, SOD, CAT, or GSH in in group treated with ZnONPs (10 mg/kg b.w./day) when compared with the normal control group, Interestingly, the concentration of MDA was highly significant (P \u0026nbsp; 0.001), while that of SOD, CAT, and GSH were significantly elevated (P \u0026nbsp;0.001) in the ZnO-NPs treated group when compared with the doxorubicin treated group.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e3.9 Interleukin-6 (IL-6) levels in renal tissue of experimental groups.\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eRenal IL-6 levels were significantly elevated in the doxorubicin-treated group compared to the normal control group. When compared to the doxorubicin-treated group, the ZnO-NPs (10 mg/kg b.w./day) group showed a highly significant decreased in renal IL-6 levels. While there was no significant change in renal IL-6 level in the group treated with ZnONPs (10 mg/kg b.w./day) when compared with the normal control group (Fig. 8),\u003c/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003cbr\u003e\u003c/p\u003e"},{"header":"4. Discussion","content":"\u003cp\u003eDOX is used to treat multiple solid tumors but has severe adverse effects on the kidneys [33\u0026ndash;35]. The mechanisms by which DOX causes glomerular toxicity are not yet fully understood. However, previous reports have shown that reactive oxygen species and free radicals are the most significant contributors to DOX-induced nephrotoxicity [35\u0026ndash;37]. DOX exerts direct toxic damage to the glomerular base membrane, podocytes, and glomerular endothelial cells, inducing tubular interstitial inflammation and fibrosis [38]. Inflammation increases ROS production, oxidative stress, apoptosis, and a decrease in antioxidant enzymes in the kidney, all of which may be underlying causes of DOX-induced renal injury [39].As a result, renal function is compromised following DOX administration; in turn, serum urea and creatinine concentrations increase while serum albumin decreases, ultimately leading to extreme proteinuria [40]. Because rat intrarenal enzyme dissemination is similar to that of humans, drug-induced improvements in kidney function and tubular lesions can be easily evaluated [41].The current study was proposed to discern the potential of ZNONPS to prevent the chemotherapeutic drugs\u0026apos; induced renal toxicity, which might enhance the antitumor efficacy of DOX. In the current research, we used a cumulative dose of DOX injections to induce an experimental nephrotic syndrome model. This model was characterized by increased serum levels of creatinine and BUN (two significant indicators of renal function) and decreased serum albumin [42], as well as an elevated level of urine albumin (one of the general indicators of kidney injury) [43], all of which are associated with increased oxidative stress and inflammatory factors. The toxic effects of DOX administration observed in the current study are consistent with the findings of previous studies in which renal function parameters, including serum urea and creatinine, increased [44, 45]. However, administering ZnONPs before, during, and after DOX injections yielded improvements in renal function parameters, including decreased serum urea, increased \u0026nbsp;creatinine, decreased urine albumin, and increased serum albumin. These improvements in DOX-induced renal dysfunction have been confirmed by histological and biochemical findings [46]. For example, DOX has been shown to increase oxidative stress in the kidneys, as indicated by changes in antioxidant status.\u003c/p\u003e\n\u003cp\u003eThe decline of SOD, CAT, and GR activities, accompanied by a decrement in GSH content, was unveiled after DOX injection, resulting in the reduced ability of the kidney to scavenge toxic H\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e2\u003c/sub\u003e and lipid peroxides. These findings were also noticed by other researchers [42]. In the present investigation, ZNONPS was able to significantly restore the above-mentioned antioxidant enzyme activities in kidney tissues. Reno-protective actions of ZNONPS against DOX-induced nephrotoxicity.\u003c/p\u003e\n\u003cp\u003eRenal MDA was found to be increased after DOX inoculation, among other oxidative stress inducers. Outcomes of the present research also indicate that there was a significant increase in MDA and H2O2 quantity in the renal tissue of rats that received DOX alone in contrast to the control group. These results were in accord with preceding studies, which demonstrated an increase in lipid peroxidation and subsidence of the antioxidant defence system in the kidney after DOX treatment [47].\u003c/p\u003e\n\u003cp\u003eThe findings show that ZNO-NPS can reverse renal injury caused by DOX treatments and confirm the importance of ZNO-NPS antioxidant properties in preventing drug-induced nephrotoxicity, specifically by enhancing the antioxidant defense system Consistently [47,48]. NF-kB is a transcription factor that regulates a wide variety of genes involved in developing renal disease [49, 50]. NF-kB activation plays a pivotal role in the pathogenesis of DOX-induced renal inflammation [51]. TNF-, IL-1, and IL-6 expression is mediated by NF-kB, which is responsible for inflammatory reactions [52, 53].\u003c/p\u003e\n\u003cp\u003eFurthermore, serum IL-6 levels were found to be higher in DOX-treated rats. The anti-inflammatory effects of ZnONPs have been described in multiple studies [54, 55, 56]. MinHo Kimet al. previously reported that ZnONPs had an anti-inflammatory effect by downregulating the expression of interleukin (IL)1, IL6, and TNF [44].Consistent with these observations, ZNO-NPS co-therapy reduced the extent to which IL-6 levels were altered by DOX. These results suggest that ZNO-NPS has anti-inflammatory effects and can reduce the harm done by DOX in harvested tissues.\u003c/p\u003e\n\u003cp\u003eDysregulation of inflammation and apoptosis is involved in DOX-induced renal injury. NF-B is involved in the signaling pathways of inflammation and apoptosis. It is reported that DOX could induce NF-B activation both in vivo and in vitro [57, 58]. However, little evidence is currently available on the relationship between DOX-induced cell apoptosis and NF-B activation. We examined the involvement of NF-B signaling molecules that have been implicated as stimulators of inflammation and apoptosis [59]. In our study, we observed that DOX-induced NF-B activation was prevented by ZNONPS. It was demonstrated that ZNONPS pretreatment decreased the expression of NF-B. Our results with ZNO-NPS show that ZNO-NPS reduces NF-B expression.\u003c/p\u003e\n\u003cp\u003eThe beneficial effects of ZnO-NPs were further illustrated by a histological evaluation using H\u0026amp;E staining, periodic acid Schiff (PAS), and Masson Trichrome. It was assumed that histopathological changes are related to the absorption capacity of renal tubules, which causes functional congestion of nephrons and subsequent kidney dysfunction [60].ZnONPs\u0026apos; treatment significantly ameliorates the damaging effects of DOX on kidney morphology. By acting as a potent quencher of radical species in the kidney, it prevents toxic influences at both the histological and biochemical levels [61]. These findings supported the hypothesis that ZnONPs could alleviate the biochemical and histological changes caused by DOX treatment. Therefore, ZnONPs might be a significant candidate, providing an excellent protective effect in combination with chemotherapy due to their antioxidant and radical species quenching potential. Our results suggest that ZNO-NPS alleviates DOX-induced nephrotic syndrome in rats, likely owing to its antioxidant and anti-inflammatory properties. These findings indicate that ZNO-NPS could be used as a therapeutic agent for DOX-induced nephrotoxicity.\u003c/p\u003e"},{"header":"Conclusion","content":"\u003cp\u003eThe present study indicates that the treatment effect of ZnO-NPs on DOX provoked kidney damage in rats. The outcomes revealed the ameliorating potential of ZnO-NPs against DOX-induced kidney injury via suppression of the effect of DOX-mediated oxidative deterioration in renal tubular cells, preservation of kidney function biomarkers, and prevention of DNA damage. ZnO-NPs offered added protection against DOX-induced kidney damage. The mechanism of nephroprotective action of the ZnO-NPs fraction could be due to the antioxidant and free radical scavenging activities of its active metabolites. The present results suggest that ZnO-NPs might be potentially therapeutic in preventing the nephrotoxic and inflammatory effects of DOX.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp style=\"text-align: left;\"\u003e\u003cstrong\u003eAcknowledgment\u003c/strong\u003e\u003c/p\u003e\n\u003cp style=\"text-align: left;\"\u003eThe authors would like to thank the Chemistry Department, Faculty of Science, Mansoura University, Egypt for providing some of the facilities required during this study. They are also thankful for the faculty of Science, Suez Canal University, Egypt for providing \u0026nbsp;facilities required for the study.\u003c/p\u003e\n\u003cp dir=\"RTL\" style=\"text-align: left;\"\u003e\u003cstrong\u003e\u003cspan dir=\"LTR\"\u003eEthics approval and consent to participate\u003c/span\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp dir=\"RTL\" style=\"text-align: left;\"\u003e\u003cspan dir=\"LTR\"\u003eNot applicable.\u003c/span\u003e\u003c/p\u003e\n\u003cp dir=\"RTL\" style=\"text-align: left;\"\u003e\u003cstrong\u003e\u003cspan dir=\"LTR\"\u003eConsent for publication\u003c/span\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp dir=\"RTL\" style=\"text-align: left;\"\u003e\u003cspan dir=\"LTR\"\u003eNot applicable.\u003c/span\u003e\u003c/p\u003e\n\u003cp style=\"text-align: left;\"\u003e\u003cstrong\u003eAvailability of data and materials:\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp style=\"text-align: left;\"\u003eThe data that supports this work is available upon reasonable request.\u0026nbsp;\u003c/p\u003e\n\u003cp style=\"text-align: left;\"\u003e\u003cstrong\u003eAuthor Contributions:\u003c/strong\u003e\u003c/p\u003e\n\u003cp style=\"text-align: left;\"\u003eThe study\u0026apos;s inception and design were contributed to by all authors.\u003c/p\u003e\n\u003cp dir=\"RTL\" style=\"text-align: left;\"\u003e\u003cstrong\u003e\u003cspan dir=\"LTR\"\u003eCompeting interests\u003c/span\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp dir=\"RTL\" style=\"text-align: left;\"\u003e\u003cspan dir=\"LTR\"\u003eThe authors declare no conflicts of interest.\u003c/span\u003e\u003c/p\u003e\n\u003cp dir=\"RTL\" style=\"text-align: left;\"\u003e\u003cstrong\u003e\u003cspan dir=\"LTR\"\u003eFunding\u003c/span\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp dir=\"RTL\" style=\"text-align: left;\"\u003e\u003cspan dir=\"LTR\"\u003eNo funding was received during the study. The study was done through self-finance.\u003c/span\u003e\u003c/p\u003e\n\u003cp dir=\"RTL\" style=\"text-align: left;\"\u003e\u003cstrong\u003e\u003cspan dir=\"LTR\"\u003e\u0026nbsp;Authors\u0026apos; information\u0026nbsp;\u003c/span\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp dir=\"RTL\" style=\"text-align: left;\"\u003e\u003csup\u003e\u003cspan dir=\"LTR\"\u003e1\u003c/span\u003e\u003c/sup\u003e\u003cspan dir=\"LTR\"\u003e, Department of Chemistry, Faculty of Science, Suez Canal University, Ismailia, Egypt , \u003csup\u003e2\u003c/sup\u003e Biochemistry Division, Chemistry Department, Faculty of Science, Mansoura University, Mansoura, 35516, Egypt.\u003c/span\u003e\u003c/p\u003e\n\u003cp style=\"text-align: left;\"\u003e\u003cstrong\u003e\u003cu\u003e*Corresponding author:\u0026nbsp;\u003c/u\u003e\u003c/strong\u003eOmali Y. El-Khawaga, Biochemistry Division, Chemistry Department, Faculty of Science, Mansoura University, Mansoura, 35516, Egypt. Email: [email protected], +201028464738\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eSiew ED, Davenport A. 2015. The growth of acute kidney injury: a rising Tide or just closer attention to detail? Kidney International, 87(1): 46\u0026ndash;61. \u003c/li\u003e\n\u003cli\u003eTomino Y. 2014. Pathogenesis and treatment of chronic kidney disease: a Review of our recent basic and clinical data. Kidney \u0026amp; Blood Pressure Research, 39(5): 450\u0026ndash;489.\u003c/li\u003e\n\u003cli\u003eChawla LS, Eggers PW, Star RA, Kimmel PL. 2014. Acute kidney injury and Chronic kidney disease as interconnected syndromes. The New England Journal of Medicine, 371(1): 58\u0026ndash;66. \u003c/li\u003e\n\u003cli\u003eMehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, et al; Acute Kidney Injury Network. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007;11:R31.\u003c/li\u003e\n\u003cli\u003eKidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl 2012;2:1-138.\u003c/li\u003e\n\u003cli\u003eHsu RK, Hsu CY. 2016. The role of acute kidney injury in chronic kidney Disease. Seminars in Nephrology, 36(4): 283\u0026ndash;292.\u003c/li\u003e\n\u003cli\u003eM. Cagel, E. Grotz, E. Bernabeu, M. A. Moretton, and D. A.Chiappetta, \u0026ldquo;Doxorubicin: nanotechnological overviews from bench to bedside,\u0026rdquo; Drug Discovery Today, vol. 22, no. 2 pp. 270\u0026ndash;281, 2017.\u003c/li\u003e\n\u003cli\u003eC. Carvalho, R. Santos, S. Cardoso et al., \u0026ldquo;Doxorubicin: the good, the bad and the ugly effect,\u0026rdquo; Current Medicinal Chemistry, vol. 16, no. 25, pp. 3267\u0026ndash;3285, 2009\u003c/li\u003e\n\u003cli\u003eShivakumar, P. ; M. U. Rani, A. G. Reddy, et al., 2012. A Study on the Toxic Effects of Doxorubicin on the Histology of Certain Organs, Toxicol. Int., 19(3), 241\u0026ndash;244, Pubmed ID: 23293460. \u003c/li\u003e\n\u003cli\u003eSah, S. K. ; S. Khatiwada, D. Chaudhary, et al., 2015,Doxorubicin Induced Histomorphometric Changes in Testes of Albino Rats, Nepal J. Biotechnol., 3(1), 10\u0026ndash;14, DOI: 10.3126/ njb.v3i1.14223. \u003c/li\u003e\n\u003cli\u003eWang YM, Wang Y, Harris DC, Alexander SI, Lee VW. Adriamycin nephropathy in BALB/c mice. Curr Protoc Im. 2015;108, 15.28.11-16.\u003c/li\u003e\n\u003cli\u003eYi M, Zhang L, Liu Y, et al. Autophagy is activated to protect against podocyte injury in adriamycin-induced nephropathy. Am J Physiol Ren Physiol. 2017;313:74e84.\u003c/li\u003e\n\u003cli\u003eLee VW, Harris DC. Adriamycin nephropathy: a model of focal segmental glomerulosclerosis. Nephrology (Carlton). 2011;16:30e38.\u003c/li\u003e\n\u003cli\u003eAva Soltani Hekmat, Ameneh Chenari, Hiva Alipanah and Kazem Javanmardi.:\u0026apos; Protective effect of alamandine on doxorubicin‑induced nephrotoxicity in rats\u0026apos;, Soltani Hekmat et al. BMC Pharmacology and Toxicology, (2021), 22:31\u003c/li\u003e\n\u003cli\u003eKantipudi, S., Sunkara, J.R., Rallabhandi, M., et al.: \u0026lsquo;Enhanced wound healing activity of Ag-ZnO composite NPs in Wistar albino rats\u0026rsquo;, IET Nanobiotechnol., 2018, 12, pp. 473\u0026ndash;478\u003c/li\u003e\n\u003cli\u003eShaaban, M., El-Mahdy, A.M.: \u0026lsquo;Biosynthesis of Ag, Se, and ZnO nanoparticles with antimicrobial activities against resistant pathogens using waste isolate Streptomyces enissocaesilis\u0026rsquo;, IET Nanobiotechnol., 2018, 12,pp. 741\u0026ndash;747\u003c/li\u003e\n\u003cli\u003eHongbo Shi , Ruth Magaye , Vincent Castranova and Jinshun Zhao. : \u0026apos;Titanium dioxide nanoparticles: a review of current toxicological data\u0026apos; ,Particle and Fibre Toxicology 2013 10(1),15\u003c/li\u003e\n\u003cli\u003eAmira Awadalla a, Abdelaziz M. Hussein , Yousra M. El-Fard, Nashwa Barakat, Eman T. Hamam, Mohamed El-Sherbiny,f, Mohamed El-Shafey, Ahmed A. Shocker. :\u0026quot;Effect of zinc oxide nanoparticles and ferulic acid on renal ischemia/ reperfusion injury: possible underlying mechanisms,\u0026quot; Biomedicine \u0026amp; Pharmacotherapy 140 (2021) 111686\u003c/li\u003e\n\u003cli\u003e[19] R.B. Gupta, U.B. Kompella, Nanoparticle technology for drug delivery. 2006.\u003c/li\u003e\n\u003cli\u003eE.S. Ali, S.M. Sharker, M.T. Islam, I.N. Khan, S. Shaw, M.A. Rahman, et al., Targeting Cancer Cells With Nanotherapeutics and Nanodiagnostics: Current Status and Future Perspectives, Semin. Cancer Biol. (2020).\u003c/li\u003e\n\u003cli\u003e[21] H. Najafzadeh, S. Ghoreishi, B. Mohammadian, E. Rahimi, M. Afzalzadeh, M. Kazemivarnamkhasti, H. Ganjealidarani, Serum biochemical and histopathological changes in liver and kidney in lambs after zinc oxide nanoparticles administration, Vet. World 6 (8) (2013) 534.\u003c/li\u003e\n\u003cli\u003e[22] D. Dhawan, V.D. Chadha, Zinc: a promising agent in dietary chemoprevention of cancer, Indian J. Med. Res. (2010) 676. Yao, S. ; X. Feng, J. Lu et al., 2018 \u0026ldquo;Antibacterial activity and inflammation inhibition of ZnO nanoparticles embedded TiO2 nanotubes,\u0026rdquo; Nanotechnology, vol. 29, no. 24, article 244003,.\u003c/li\u003e\n\u003cli\u003eP. Nagajyothi, S.J. Cha, I.J. Yang, T. Sreekanth, K.J. Kim, H.M. Shin, Antioxidant and anti-inflammatory activities of zinc oxide nanoparticles synthesized using Polygala tenuifolia root extract, J. Photochem. Photobiol. B Biol. 146 (2015) 10\u0026ndash;17.\u003c/li\u003e\n\u003cli\u003e[24] M. Afifi, A.M. Abdelazim, Ameliorative effect of zinc oxide and silver nanoparticles on antioxidant system in the brain of diabetic rats, Asian Pac. J. Trop. Biomed. 5 (10) (2015) 874\u0026ndash;8\u003c/li\u003e\n\u003cli\u003eYao, S. ; X. Feng, J. Lu et al., \u0026ldquo;Antibacterial activity and inflammation inhibition of ZnO nanoparticles embedded TiO2 nanotubes,\u0026rdquo; Nanotechnology, vol. 29, no. 24,2018, article 244003\u003c/li\u003e\n\u003cli\u003eZeynab Khamis El-Maddawya and Walaa Slouma Hamouda Abd El Nab.: \u0026apos; Protective effects of zinc oxide nanoparticles against doxorubicin induced testicular toxicity and DNA damage in male rats\u0026apos;,Toxicol. Res., 2019, 8, 654\u0026ndash;662\u003c/li\u003e\n\u003cli\u003eMai Abdel Hamid Eita1,Rehab Hamdy Ashour,Omali Youssef El-Khawaga:. \u0026quot;Pentosan polysulfate exerts anti-inflammatory effect and halts albuminuria progression in diabetic nephropathy Role of combined losartan, \u0026quot;Fundam Clin Pharmacol. 2022;36:801\u0026ndash;810 \u003c/li\u003e\n\u003cli\u003eTabacco A, Meiattini F, Moda E, Tarli P. Simplifiednenzymic/colorimetric serum urea nitrogen determination. Clin Chem. 1979;25(2):336-337. doi:10.1093/clinchem/25.2.336a\u003c/li\u003e\n\u003cli\u003eB. T. Doumas, T. Peters,\u0026quot; Serum and urine albumin: a progress report on their measurement and clinical significance\u0026quot;, Clin. Chim. Acta 1997, 258(1), 3\u0026ndash;20. doi.org/10.1016/S0009-8981(96)06447-9\u003c/li\u003e\n\u003cli\u003eSchosinsky KH, Vargas M, Luz Esquivel A, Chavarria MA. Simple spectrophotometric determination of urinary albumin by dyebinding with use of bromphenol blue. Clin Chem. 1987;33(2 Pt.\u003c/li\u003e\n\u003cli\u003eAva Soltani Hekmat, Ameneh Chenari, Hiva Alipanah and Kazem Javanmardi\u0026quot; ,Protective effect of alamandine on Doxorubicin‑induced nephrotoxicity in rats ,\u0026quot;BMC Pharmacology and Toxicology (2021) 22:31\u003c/li\u003e\n\u003cli\u003eBancroft, J.D., Stevens, A.: \u0026lsquo;Theory and practice of histological techniques\u0026rsquo;(Churchill Livingstone, Edinburgh, 1990, 3rd edn.)\u003c/li\u003e\n\u003cli\u003eAva Soltani Hekmat, Ameneh Chenari, Hiva Alipanah and Kazem Javanmardi\u0026quot; ,Protective effect of alamandine on Doxorubicin‑induced nephrotoxicity in rats ,\u0026quot;BMC Pharmacology and Toxicology (2021) 22:31\u003c/li\u003e\n\u003cli\u003eSaad SY, Najjar TA, Al-Rikabi AC. The preventive role of deferoxamine against acute doxorubicin-induced cardiac, renal and hepatic toxicity in rats. Pharmacol Res. 2001;43(3):211\u0026ndash;8.\u003c/li\u003e\n\u003cli\u003eHussain MA, Abogresha NM, AbdelKader G, Hassan R, Abdelaziz EZ, Greish SM. Antioxidant and Anti-Inflammatory Effects of Crocin Ameliorate Doxorubicin-Induced Nephrotoxicity in Rats. Oxid Med Cell Longev. 2021; .2021:8841726\u003c/li\u003e\n\u003cli\u003eLiu LL, Li QX, Xia L, Li J, Shao L. Differential effects of dihydropyridine calcium antagonists on doxorubicin-induced nephrotoxicity in rats. Toxicology. 2007;231(1):81\u0026ndash;90.\u003c/li\u003e\n\u003cli\u003e[37]. De Beer EL, Bottone AE, Voest EE. Doxorubicin and mechanical performance of cardiac trabeculae after acute and chronic treatment: A review. Eur J Pharmacol. 2001;415(1):1\u0026ndash;11.\u003c/li\u003e\n\u003cli\u003eJeansson M, Bj\u0026ouml;rck K, Tenstad O, Haraldsson B. Adriamycin alters glomerular endothelium to induce proteinuria. J Am Soc Nephrol. 2009;20(1):114\u0026ndash;22.\u003c/li\u003e\n\u003cli\u003eTayyaba Afsar, Suhail Razak , Ali Almajwal, Dara Al-Disi,\u0026quot; Doxorubicin-induced alterations in kidney functioning, oxidative stress,DNA damage, and renal tissue morphology; Improvement by Acacia hydaspica tannin-rich ethyl acetate fraction\u0026quot;,T. Afsar et al. / Saudi Journal of Biological Sciences 27 (2020) 2251\u0026ndash;2260.\u003c/li\u003e\n\u003cli\u003eWu Q, Li W, Zhao J, Sun W, Yang Q, Chen C, et al. Apigenin ameliorates doxorubicin-induced renal injury via inhibition of oxidative stress and inflammation. Biomed Pharmacother. 2021;137:111308.\u003c/li\u003e\n\u003cli\u003e[41] Saad, A.A., Youssef, M.I., El-Shennawy, L.K., 2009. Cisplatin induced damage in kidney genomic DNA and nephrotoxicity in male rats: the protective effect of grape seed proanthocyanidin extract. Food Chem. Toxicol. 47, 1499\u0026ndash;1506.\u003c/li\u003e\n\u003cli\u003eEl-Sheikh, A.A., Morsy, M.A., Mahmoud, M.M., Rifaai, R.A., Abdelrahman, A.M., 2012. Effect of coenzyme-Q10 on doxorubicin-induced nephrotoxicity in rats. Adv. Pharm. Sci.\u003c/li\u003e\n\u003cli\u003eDhondup, T., Qian, Q., 2017. Electrolyte and acid-base disorders in chronic kidney disease and end-stage kidney failure. Blood Purificat. 43, 179\u0026ndash;188.\u003c/li\u003e\n\u003cli\u003eKoul A, Shubrant, Gupta P. Phytomodulatory potential of lycopene from Lycopersicum esculentum against doxorubicin induced nephrotoxicity. Indian J Exp Biol. 2013;51(8):635\u0026ndash;45.\u003c/li\u003e\n\u003cli\u003eMancilla TR, Iskra B, Aune GJ. Doxorubicin-induced cardiomyopathy in Children. Compr Physiol. 2019 ;9(3):905\u0026ndash;931.\u003c/li\u003e\n\u003cli\u003eLamiaa A.A. Barakata, Nashwa Barakatb, Mahmoud M. Zakariab, Salma M. Khirallaha,\u0026quot; Protective role of zinc oxide nanoparticles in kidney injury induced by cisplatin in rats\u0026quot; Life Sciences 262 (2020) 118503.\u003c/li\u003e\n\u003cli\u003eAzza A. K. El-Sheikh,Mohamed A. Morsy, Marwa M. Mahmoud,Rehab A. Rifaai, and Aly M. Abdelrahman\u0026quot; Effect of Coenzyme-Q10 on Doxorubicin-Induced Nephrotoxicity in Rats, Volume 2012, Article ID 981461, 8 pages.\u003c/li\u003e\n\u003cli\u003eAmira Awadalla, Abdelaziz M. Hussein , Yousra M. El-Fard, Nashwa Barakat, Eman T. Hamama, Mohamed El-Sherbinye, Mohamed El-Shafey, Ahmed A. Shokei \u0026quot; ,rEffect of zinc oxide nanoparticles and ferulic acid on renal ischemia/ reperfusion injury: possible underlying mechanisms\u0026quot;Biomedicine \u0026amp; Pharmacotherapy 140 (2021) 111686.\u003c/li\u003e\n\u003cli\u003e[49] Sanz AB, Sanchez-Ni\u0026ntilde;o MD, Ramos AM, Moreno JA, Santamaria B, RuizOrtega M, et al. NF-\u0026kappa;B in renal inflammation. J Am Soc Nephrol. 2010;21(8): 1254\u0026ndash;62.\u003c/li\u003e\n\u003cli\u003eAboyoussef AM, Abdel-Sattar AR, Abdel-Bakky MS, Messiha BAS. Enoxaparin prevents CXCL16/ADAM10-mediated cisplatin renal toxicity: Role of the coagulation system and the transcriptional factor NF-\u0026kappa;B. Life Sci. 2021;270:119120.\u003c/li\u003e\n\u003cli\u003eSutariya B, Saraf M. \u0026alpha;-asarone reduce proteinuria by restoring antioxidant enzymes activities and regulating necrosis factor \u0026kappa;B signaling pathway in doxorubicin-induced nephrotic syndrome. Biomed Pharmacother. 2018;98:318\u0026ndash;324.\u003c/li\u003e\n\u003cli\u003eVyas D, Laput G, Vyas AK. Chemotherapy-enhanced inflammation may lead to the failure of therapy and metastasis. OncoTargets and Therapy. 2014;7:1015\u0026ndash;23.\u003c/li\u003e\n\u003cli\u003eSomade OT, Ajayi BO, Safiriyu OA, Oyabunmi OS, Akamo AJ. Renal and testicular up-regulation of pro-inflammatory chemokines (RANTES and CCL2) and cytokines (TNF-\u0026alpha;, IL-1\u0026beta;, IL-6) following acute edible camphor administration is through activation of NF-kB in rats. Toxicol Reports. 2019;6:759\u0026ndash;767.\u003c/li\u003e\n\u003cli\u003eNagajyothi, P., et al.: Antioxidant and anti‐inflammatory activities of zinc oxide nanoparticles synthesised using polygala tenuifolia root extract. J. Photoch. Photobio. B. 146, 10\u0026ndash;17 (2015)\u003c/li\u003e\n\u003cli\u003eKim, M.H., et al.: Zinc oxide nanoparticles, a novel candidate for the treatment of allergic inflammatory diseases. Eur. J. Pharmacol. 738,31\u0026ndash;39 (2014)\u003c/li\u003e\n\u003cli\u003e[56]Adamcakova‐Dodd, A., et al.: Toxicity assessment of zinc oxide nanoparticles using sub‐acute and sub‐chronic murine inhalation models. Part. Fibre Toxicol. 11(1), 15 (2014)\u003c/li\u003e\n\u003cli\u003eRasha E. Mostafa, Dalia O. Saleh, Dina F. Mansour\u0026quot;,Cisplatin-Induced Nephrotoxicity in Rats: Modulatory Role of Simvastatin and Rosuvastatin against Apoptosis and Inflammation\u0026quot; ,Journal of Applied Pharmaceutical Science Vol. 8(04), pp 043-050, April, 2018\u003c/li\u003e\n\u003cli\u003eDavoud Sanajou \u0026amp; Saeed Nazari Soltan Ahmad \u0026amp; Vahid Hosseini \u0026amp; Ashkan Kalantary-Charvadeh \u0026amp;Yasser Marandi \u0026amp; Leila Roshangar \u0026amp; Saman Bahrambeigi \u0026amp; Mehran Mesgari-Abbasi\u0026quot;, \u0026beta;-Lapachone protects against doxorubicin-induced nephrotoxicity via NAD+/AMPK/NF-kB in mice\u0026quot;,Naunyn-Schmiedeberg\u0026apos;s Archives of Pharmacology (2019) 392:633\u0026ndash;640.\u003c/li\u003e\n\u003cli\u003eWang S, Kotamraju S, Konorev E, Kalivendi S, Joseph J, Kalyanaraman B. Activation of nuclear factor-\u0026kappa;B during doxorubicin-induced apoptosis in endothelial cells and myocytes is pro-apoptotic: The role of hydrogen peroxide. Biochem J. 2002;367(Pt 3):729\u0026ndash;40\u003c/li\u003e\n\u003cli\u003eKhan, R.A., Khan, M.R., Sahreen, S., 2012. Protective effects of rutin against potassium bromate induced nephrotoxicity in rats. BMC Complement. Alternative Med. 12, 204.\u003c/li\u003e\n\u003cli\u003eShahbazi, F., Dashti-Khavidaki, S., Khalili, H., Lessan-Pezeshki, M., 2012. Potential renoprotective effects of silymarin against nephrotoxic drugs: a review of literature. J. Pharm. Pharm. Sci. 15, 112\u0026ndash;123.\u003c/li\u003e\n\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Doxorubicin, Kidney Injury, Oxidative stress, Zinc oxide Nanopartcle Gene expression.","lastPublishedDoi":"10.21203/rs.3.rs-2814493/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-2814493/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"This study evaluated the biochemical, molecular, and histopathological mechanisms involved in renal injury and the effect of zinc oxide nanoparticles (ZnONPs) in experimental nephrotoxicity rats. ZnONPs were prepared by the sol–gel method and characterised by scanning and transmission electron microscopy (SEM and TEM). To explore the possible nephrotoxicity and antioxidant effect of ZnONPs, rats were grouped as follows: control group, ZnONPs-treated group, Doxorubicin group, and ZnONPs-Doxorubicin-treated group. Upon treatment with ZnONPs, a significant alteration was observed in the activities of superoxide dismutase, glutathione peroxidase, malondialdehyde, catalase, and the levels of kidney function, albumin, albuminuria, immune nuclear factor kappa B (NF-B), and interleukin-6 (IL-6) compared to the Doxorubicin group and control group. ZnONPs' administration to the doxorubicin group showed eminent renal injury control and restoration of the biochemical profile. This increases their active role in controlling kidney function in order to improve nephrotoxicity and inflammatory responses. Histopathological and immunohistochemical observations provided context for these findings. In conclusion, ZnO-NPs treatment revealed a renoprotective effect against the doxorubicin drug, probably via its antioxidant, anti-inflammatory, and anti-apoptotic properties. This shows the therapeutic application of ZnONPs as a safe anti-inflammatory and shows their potential for the control of renal injury.","manuscriptTitle":"Zinc oxide nanoparticles regulate NF-kB expression and restrict inflammation response in Doxorubicin- induced kidney injury in rats","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2023-04-17 14:37:16","doi":"10.21203/rs.3.rs-2814493/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"9329c867-2dc1-47dc-9406-21fcc3b00afb","owner":[],"postedDate":"April 17th, 2023","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2023-04-17T14:45:18+00:00","versionOfRecord":[],"versionCreatedAt":"2023-04-17 14:37:16","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-2814493","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-2814493","identity":"rs-2814493","version":["v1"]},"buildId":"_2-kVJe1T_tPrBINL-cwx","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}